Biogen tested the drug for lupus in a mid-stage study. Study results indicate that the drug improves skin clearance in lupus patients. The study focused on the drug's effectiveness in reducing the skin manifestations of lupus. Additionally, the article mentions Insilico's extensive deal with Eli Lilly. Takeda presented data from the third phase of the study focused on the treatment of psoriasis. In addition, the article also brings other news from the field of biotechnology.